Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently moved to the United States, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical topics, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial article.
 
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published a
Lot of experimental research articles and theoretical papers as lead
Author. The abovementioned sole-author publications
Discussed two crucial themes.
The first of those discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The outcomes and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author works is a research methodology to come up with knowledge via
Bringing several facts together from seemingly unrelated fields.
This results in new concepts with testable predictions, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important result revealed by Dr. Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Inhibiting body aging — in other words, “preventing cancer
Via remainng young. ” His lab closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medications beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin as well as other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging medications to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482593/

https://peterattiamd.com/targeting-aging/

https://en.wikipedia.org/wiki/Mikhail_Blagosklonny